Stocks Health care CUE
NASDAQ · Health careCue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. brought in $37.7M of revenue over the twelve months to June 30, 2026, up 354.4% from a year earlier. It posted a net loss of $164.1M. In fiscal 2025 capital spending exceeded operating cash flow by $21.9M. At June 30, 2026 it held $17.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Cue Biopharma, Inc.
- Net worth
- Cue Biopharma, Inc. has a market value (market cap) of $136.3M at the latest share price, and shareholders' equity of $2.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $27.5M (+195.7% year on year), with a net loss of $26.6M. Over the 12 months to June 30, 2026: revenue $37.7M, net loss $164.1M.
- Cash flow
- In fiscal 2025 operations used $21.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cue Biopharma, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Cue Biopharma, Inc. does
Cue Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CUE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $27.5M | -$26.6M | -$0.28 | -$21.9M |
| 2024 | $9.3M | -$40.7M | -$0.72 | -$36.4M |
| 2023 | $5.5M | -$50.7M | -$1.11 | -$40M |
| 2022 | $1.2M | -$53M | -$1.49 | -$42M |
| 2021 | $14.9M | -$44.2M | -$1.41 | -$39.8M |
| 2020 | $3.2M | -$44.8M | -$1.56 | -$33.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CUE ranks in Health care
Latest SEC filings
What Cue Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 8, 2026Passive stake changed SCHEDULE 13G/A
- September 21, 2026
- August 21, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 167% to $7.9M versus the same quarter last year; diluted EPS -$24.14 versus -$2.67.
- August 14, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 3, 2026
- July 10, 2026
- June 18, 2026
Insider trades
What the people running Cue Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.3M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 12, 2026 | Ray SumitaChief Legal Compliance Officer | Sold | 1,844 | $51.7K |
| October 12, 2026 | Lin Shao-LeeChief Executive Officer, Director | Sold | 10,000 | $275K |
| October 12, 2026 | Lin Shao-LeeChief Executive Officer, Director | Sold | 1,087 | $30.5K |
| October 12, 2026 | Meluzio Michael VincentVP, Prin. Accounting Officer | Sold | 1,144 | $32.1K |
| August 13, 2026 | Ray SumitaChief Legal Compliance Officer | Exercised options | 18,196 | - |
| August 13, 2026 | Ray SumitaChief Legal Compliance Officer | Sold | 2,383 | $70K |
| August 13, 2026 | Ray SumitaChief Legal Compliance Officer | Sold | 6,442 | $195.5K |
| August 13, 2026 | Ray SumitaChief Legal Compliance Officer | Sold | 4 | $124.5 |
Who owns CUE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bleichroeder LP13G, passive with 2 related filers | 9.99% | March 21, 2025 |
| Mark E. Strome13G, passive with 5 related filers | 8.5% | October 8, 2026 |
| Driehaus Capital Management LLC13G, passive | 6.96% | August 14, 2026 |
| Shao-Lee Lin13D, may seek influence | 6.2% | August 21, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 49 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bleichroeder LP | 370,682 | new |
| Driehaus Capital Management LLC | 292,144 | new |
| Vanguard Capital Management LLC | 161,700 | new |
| Ikarian Capital, LLC | 104,364 | new |
| Tetragon Partners GP Ltd | 93,819 | new |
| Stempoint Capital LP | 66,995 | new |
| BlackRock, Inc. | 57,807 | new |
| ADAR1 Capital Management, LLC | 55,193 | new |
| Lion Point Capital, LP | 52,928 | new |
| Squadron Capital Management LLC | 50,000 | new |
| Diadema Partners LP | 48,369 | new |
| Geode Capital Management, LLC | 47,824 | new |
| Boothbay Fund Management, LLC | 31,459 | new |
| UBS Group AG | 26,700 | new |
| Citadel Advisors LLC | 25,633 | new |
| Vanguard Fiduciary Trust Co | 24,476 | new |
| Texas Capital Bank Wealth Management Services Inc | 22,881 | new |
| Renaissance Technologies LLC | 14,689 | new |
| Persistent Asset Partners Ltd | 12,332 | new |
| Robertson Stephens Wealth Management, LLC | 11,133 | new |
Insiders
9 insiders reported holding 1,008,121 shares in total, about $18.9M at the last price.
| Holder | Shares |
|---|---|
| Lin Shao-LeeChief Executive Officer, Director | 694,908 |
| Ray SumitaChief Legal Compliance Officer | 116,701 |
| Meluzio Michael VincentVP, Prin. Accounting Officer | 47,817 |
| Borie Dominique ChristianChief Medical Officer | 31,500 |
| Sarraf PashaDirector | 29,195 |
| Ahlers James MChief Financial Officer | 25,500 |
| Meehan Viola MongDirector | 21,800 |
| Camardo Daniel A.Director | 21,800 |
| Garzone PamelaDirector | 18,900 |
Questions about CUE
What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as CUE. Its shares trade on NASDAQ under the ticker CUE.
What is Cue Biopharma, Inc.'s net worth?
Cue Biopharma, Inc. has a market value (market cap) of $136.3M at the latest share price, and shareholders' equity of $2.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cue Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $164.1M on revenue of $37.7M.
How much revenue does Cue Biopharma, Inc. make?
Over the twelve months to June 30, 2026 Cue Biopharma, Inc. reported revenue of $37.7M. That is 354.4% more than a year earlier.
When did Cue Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 14, 2026.
When is Cue Biopharma, Inc.'s next earnings report?
Cue Biopharma, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CUE with
Follow CUE
Get an email when Cue Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cue Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.